Publication:
MET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American Non-Small-Cell Lung Cancer Patients

Simple item page
dc.contributor.authorRivas, Solange
dc.contributor.authorSepúlveda, Romina V.
dc.contributor.authorTapia, Ignacio
dc.contributor.authorEstay, Catalina
dc.contributor.authorSoto, Vicente
dc.contributor.authorBlanco, Alejandro
dc.contributor.authorGonzález, Evelin
dc.contributor.authorArmisen, Ricardo
dc.date.accessioned2024-12-27T15:37:14Z
dc.date.available2024-12-27T15:37:14Z
dc.date.issued2024
dc.description.abstractTargeted therapy indications for actionable variants in non-small-cell lung cancer (NSCLC) have primarily been studied in Caucasian populations, with limited data on Latin American patients. This study utilized a 52-genes next-generation sequencing (NGS) panel to analyze 1560 tumor biopsies from NSCLC patients in Chile, Brazil, and Peru. The RNA sequencing reads and DNA coverage were correlated to improve the detection of the actionable MET exon 14 skipping variant (METex14). The pathogenicity of MET variants of uncertain significance (VUSs) was assessed using bioinformatic methods, based on their predicted driver potential. The effects of the predicted drivers VUS T992I and H1094Y on c-MET signaling activation, proliferation, and migration were evaluated in HEK293T, BEAS-2B, and H1993 cell lines. Subsequently, c-Met inhibitors were tested in 2D and 3D cell cultures, and drug affinity was determined using 3D structure simulations. The prevalence of MET variants in the South American cohort was 8%, and RNA-based diagnosis detected 27% more cases of METex14 than DNA-based methods. Notably, 20% of METex14 cases with RNA reads below the detection threshold were confirmed using DNA analysis. The novel actionable T992I and H1094Y variants induced proliferation and migration through c-Met/Akt signaling. Both variants showed sensitivity to crizotinib and savolitinib, but the H1094Y variant exhibited reduced sensitivity to capmatinib. These findings highlight the importance of RNA-based METex14 diagnosis and reveal the drug sensitivity profiles of novel actionable MET variants from an understudied patient population
dc.description.versionVersión publicada
dc.format.extent20 p.
dc.identifier.citationRivas, S.; Sepúlveda, R.V.; Tapia, I.; Estay, C.; Soto, V.; Blanco, A.; González, E.; Armisen, R. MET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American Non-Small-Cell Lung Cancer Patients. Int. J. Mol. Sci. 2024, 25, 13715. https://doi.org/10.3390/ ijms252413715
dc.identifier.doihttps://doi.org/10.3390/ ijms252413715
dc.identifier.urihttps://hdl.handle.net/11447/9537
dc.language.isoen
dc.rightsAtribución-NoComercial-CompartirIgual 3.0 Chile (CC BY-NC-SA 3.0 CL)
dc.subjectNon-small-cell lung cancer
dc.subjectNovel actionable variants
dc.subjectC-Met inhibitors
dc.subjectMET exon 14 skipping
dc.subjectNext-generation sequencing
dc.titleMET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American Non-Small-Cell Lung Cancer Patients
dc.typeArticle
dcterms.accessRightsAcceso abierto
dcterms.sourceInternational Journal of Molecular Sciences
dspace.entity.typePublication
relation.isAuthorOfPublicationf814e5ac-2623-4a1f-bc2b-5a1a260ee316
relation.isAuthorOfPublication.latestForDiscoveryf814e5ac-2623-4a1f-bc2b-5a1a260ee316

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijms-25-13715-with-cover.pdf
Size:
2.79 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
347 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services